Anti-IL1 treatment in colchicine-resistant paediatric FMF patients: real life data from the HELIOS registry.

Sag E., Akal F., Atalay E., Akca Ü., Demir S., Demirel D., ...Daha Fazla

Rheumatology (Oxford, England), cilt.59, ss.3324-3329, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 59
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1093/rheumatology/keaa121
  • Dergi Adı: Rheumatology (Oxford, England)
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CINAHL, EMBASE, International Pharmaceutical Abstracts, MEDLINE
  • Sayfa Sayıları: ss.3324-3329
  • Anahtar Kelimeler: colchicine, resistant, intolerant, FMF, anakinra, canakinumab, anti-IL1, HELIOS, FAMILIAL MEDITERRANEAN FEVER, CANAKINUMAB, ANAKINRA, CHILDREN, EFFICACY
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Objectives. FMF is a prototype of autoinflammatory diseases associated with excess IL1 production. Anti-IL1 treatments are the first-line alternatives in colchicine-resistant/intolerant FMF patients. We aimed to investigate the efficacy and safety of anti-IL1 treatment in paediatric FMF patients in our local [Hacettepe univErsity eLectronlc research fOrmS (HELIOS)] registry.